Aditxt, Inc., a biotech company based in Delaware, filed an Amendment No. 1 to Form S-3 on Form S-1 with the U.S. Securities and Exchange Commission (SEC) on September 11, 2024. This amendment converts a previously filed Registration Statement on Form S-3 into a Registration Statement on Form S-1. The company, headquartered in Mountain View, California, is led by CEO Amro Albanna. The prospectus summary indicates that Aditxt is offering up to $150,000,000 of common stock to Seven Knots, LLC under a common stock purchase agreement dated May 2, 2024. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'ADTX.' As of September 10, 2024, the stock was priced at $0.496 per share. Aditxt's business model involves securing, growing, and monetizing...Show More

Aditxt, Inc., a biotech company based in Delaware, filed an Amendment No. 1 to Form S-3 on Form S-1 with the U.S. Securities and Exchange Commission (SEC) on September 11, 2024. This amendment converts a previously filed Registration Statement on Form S-3 into a Registration Statement on Form S-1. The company, headquartered in Mountain View, California, is led by CEO Amro Albanna. The prospectus summary indicates that Aditxt is offering up to $150,000,000 of common stock to Seven Knots, LLC under a common stock purchase agreement dated May 2, 2024. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'ADTX.' As of September 10, 2024, the stock was priced at $0.496 per share. Aditxt's business model involves securing, growing, and monetizing health innovations, with a focus on immune health, precision health, population health, women's health, and neurologic health. The company has several programs in various stages of development and seeks to acquire complementary assets through strategic transactions. Aditxt has entered into several agreements, including clinical trial agreements with Mayo Clinic and licensing agreements with Stanford University and MDNA Life Sciences, Inc. The company has also formed subsidiaries such as Adimune and Pearsanta to advance its therapeutic and diagnostic technologies. Additionally, Aditxt has entered into an asset purchase agreement to acquire antiviral products and has agreements related to senior notes and an equity line of credit. The company has also filed an amendment to its Certificate of Incorporation to increase authorized common stock and has entered into an amended and restated merger agreement with Evofem Biosciences, Inc.